Please login to the form below

Not currently logged in
Email:
Password:

Immunomedics

This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

Trodelvy, which Gilead acquired as part of its $21bn buyout of Immunomedics, is an antibody-drug conjugate (ADC) targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumours

Latest news

  • Kite and Oxford BioTherapeutics sign oncology research pact Kite and Oxford BioTherapeutics sign oncology research pact

    The separation allowed Gilead to focus on its other oncology projects and programmes – which now include its most recent oncology buyout of Immunomedics for $12bn. ... Immunomedics is also seeking approval in the EU for Trodelvy in the first half of

  • Gilead agrees $21bn buyout of Immunomedics Gilead agrees $21bn buyout of Immunomedics

    The  transaction will see Gilead purchase Immunomedics for $88 per share, for a total value of $21bn, and is expected to close during the fourth quarter of the year. ... Immunomedics is also seeking approval in the EU for Trodelvy in the first half of

  • Immunomedics craters after FDA rejects breast cancer ADC Immunomedics craters after FDA rejects breast cancer ADC

    Regulator wants to see more data on manufacturing. Shares in Immunomedics have gone into steep decline after the FDA rejected its breast cancer drug sacituzumab govitecan. ... Immunomedics’ management also expressed surprise at the rejection,

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’ IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’ CEO

More from news
Approximately 5 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    the first siRNA-based inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) to win approval; and Immunomedics’s sacituzumab govitecan, which is poised become the first antibody-drug conjugate to ... 9. Immunomedic’s sacituzumab govitecan

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... metastases.  The acquisition helps to bolster Seattle's late stage pipeline and comes at a lower price tag than

  • Deal Watch March 2017 Deal Watch March 2017

    In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Pharma deals during October 2013 Pharma deals during October 2013

    The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... there may be potentially good prospects for Immunomedics to find another partner once the dust has settled. .

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...